
– TSX:MSCL.TO
stock price today
stock price monthly change
stock price quarterly change
key metrics
Market Cap | 95.28M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | N/A |
Income | N/A |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freestock price history
stock forecast
financial statements
2020 | 0 | -1.57M | |
---|---|---|---|
2023 | 0 | -15.88M |
2023 | 44298000 | 3.62M | 8.18% |
---|
other data
-
What's the price of stock today?
One share of stock can currently be purchased for approximately $0.5.
-
When is 's next earnings date?
Unfortunately, 's (MSCL.TO) next earnings date is currently unknown.
-
Does pay dividends?
No, does not pay dividends.
-
How much money does make?
has a market capitalization of 95.28M.
-
What is 's stock symbol?
null is traded on the TSX under the ticker symbol "MSCL.TO".
-
What is 's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ?
Shares of can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
When went public?
null is publicly traded company for more then 17 years since IPO on 7 Jan 2008.
-
What is 's official website?
The official website for is satellos.com.
-
Where are 's headquarters?
is headquartered at Royal Bank Plaza, Toronto, ON.
-
How can i contact ?
's mailing address is Royal Bank Plaza, Toronto, ON.
company profile:
TSX
0
Biotechnology
Healthcare
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Toronto, ON M5J 2J1
:
ISIN: CA80401L3083
: